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Fragile X syndrome (FXS) is the leading inherited
cause of autism and intellectual disability. Aberrant
synaptic translation has been implicated in the
etiology of FXS, but most lines of research on
therapeutic strategies have targeted protein syn-
thesis indirectly, far upstream of the translation
machinery. We sought to perturb p70 ribosomal S6
kinase 1 (S6K1), a key translation initiation and elon-
gation regulator, in FXS model mice. We found that
genetic reduction of S6K1 prevented elevated
phosphorylation of translational control molecules,
exaggerated protein synthesis, enhanced mGluR-
dependent long-term depression (LTD), weight gain,
andmacro-orchidism in FXSmodel mice. In addition,
S6K1 deletion prevented immature dendritic spine
morphology and multiple behavioral phenotypes,
including social interaction deficits, impaired novel
object recognition, and behavioral inflexibility. Our
results support the model that dysregulated protein
synthesis is the key causal factor in FXS and that
restoration of normal translation can stabilize periph-
eral and neurological function in FXS.
INTRODUCTION
The past two decades has witnessed an explosion in research
pertaining to fragile X syndrome (FXS) and associated disorders.
FXS is a monogenic syndrome that is the leading genetic cause
of inherited mental disability and autism (Penagarikano et al.,
2007). FXS is caused by an unstable expansion of CGG repeats
in the 50UTR of the Fmr1 gene, causing hypermethylation and
subsequent silencing of the gene (Verkerk et al., 1991). The
transcriptional silencing results in the loss of expression of the
fragile X mental retardation protein (FMRP), which is an RNA-
binding protein responsible for regulating the translation of
specific sets of mRNA (Darnell et al., 2011).FMRP is involved in different aspects of RNA metabolism,
including trafficking of RNP particles, translation of specific
mRNA transcripts via regulation of translation initiation and elon-
gation, and targeted degradation via the RISC complex (Jin et al.,
2004; Kao et al., 2010; Melko and Bardoni, 2010; Park et al.,
2008). In addition, exaggerated protein synthesis has been
observed in multiple brain regions Fmr1 knockout mice (Fmr1
KO) (Qin et al., 2005). Activation of multiple GPCR-mediated
pathways have been shown to induce protein synthesis-depen-
dent long-term depression (LTD) via FMRP (Volk et al., 2007;
Zhang and Alger, 2010), and these forms of LTD are enhanced
in Fmr1 KOmice (Hou et al., 2006; Huber et al., 2002). Reduction
of mGluR5 signaling by crossing Fmr1 KO mice with Grm5
heterozygotic KO mice corrected the exaggerated protein
synthesis phenotype (Do¨len et al., 2007), consistent with the
‘‘mGluR theory’’ of FXS (Bear et al., 2004). Moreover, cognitive
deficits in a Drosophilamodel of FXS can be rescued by general
protein synthesis inhibitors (Bolduc et al., 2008). However, little
effort has been focused on directly modulating the regulation
of the translational control machinery to prevent phenotypes
observed in mouse models of FXS.
The protein kinase mammalian target of rapamycin (mTOR)
is a vital regulator of translation across all tissues and affects
cell growth, proliferation, and autophagy (Hoeffer and Klann,
2010). mTOR in association with Raptor forms mTOR complex
1 (mTORC1), which is a necessary signaling component of
long-lasting, protein-synthesis-dependent synaptic plasticity
and memory (Costa-Mattioli et al., 2009; Richter and Klann,
2009). Not only is mTORC1 signaling triggered downstream of
group I mGluRs activation and required for mGluR-LTD (Hou
and Klann, 2004), but it also was shown to be dysregulated in
Fmr1 KO mice (Sharma et al., 2010). In addition, hyperrespon-
sive ERK signaling has been shown to directly influence the
elevated translation rates observed in Fmr1 KO mice (Osterweil
et al., 2010). p70 ribosomal S6 kinase 1 (S6K1) is a common
downstream effector of both mTORC1 and ERK signaling and
plays a direct role in regulating translation. S6K1 controls
translation by phosphorylating ribosomal protein S6 and eIF
4B, facilitates eIF4A helicase activity by phosphorylating
PDCD4, promotes peptide elongation via its actions on eEF2
Kinase, and regulates the exon-junction complex functions byNeuron 76, 325–337, October 18, 2012 ª2012 Elsevier Inc. 325
Figure 1. Increased Phosphorylation of
Translation Control Molecules and Exag-
gerated Protein Synthesis in Fmr1 KO Mice
Are Corrected in dKO Mice
(A) Representative western blots of whole hippo-
campal lysates from WT, Fmr1 KO (Fmr1), S6K1
KO (S6K1), and dKO mice that were probed for
basal levels of phosphorylated S6 (p-S6) and
eIF4B.
(B) All ratios shown in cumulative graph were
normalized first to levels of total S6 and eIF4B and
then expressed relative to WT. n = 9 mice for each
genotype. *p < 0.05 and **p < 0.01, with a two-way
ANOVA (Fmr1 3 S6K1) followed by Bonferroni
post hoc tests.
(C) Representative western blots of lysates from
hippocampal slices incubated with puromycin to
measure basal rates of protein synthesis. Sensi-
tivity of the SUnSET methods to detect changes in
rates of protein synthesis is demonstrated in Fig-
ure S1C. See also Lee et al. (2005).
(D) Cumulative graphwith ratios expressed relative
to WT. n = 4 mice per genotype, two to three slices
per condition. *p < 0.05, by Kruskal-Wallis followed
by Dunn’s multiple comparisons post hoc tests
(genotypes compared to WT).
Error bars, SEM. See also Figures S1 and S2.
Neuron
Removing S6K1 Corrects FXS Phenotypes in Miceactivating SKAR (Holz et al., 2005; Ma et al., 2008; Raught et al.,
2004; Wang et al., 2001). In addition, S6K1 is an FMRP kinase
and regulates expression of LTD-relevant proteins such as
SAPAP3 (Narayanan et al., 2008), and phosphorylation of S6K1
at the mTORC1 site is elevated in Fmr1 KO mice (Sharma
et al., 2010). Finally, recent studies using lymphocytes and brain
tissue derived from FXS patients showed an upregulation of
S6K1 phosphorylation compared to normal controls (Hoeffer
et al., 2012). Thus, it is possible that depressing S6K1 activity
in FXS model mice could reverse the exaggerated protein
synthesis and thereby correct multiple phenotypes displayed
by FXS mice.
Herein, we evaluated whether S6K1 could be a viable target
for correcting phenotypes in FXS model mice. We generated
mice with a genetic deletion of S6K1 in the Fmr1 KO back-
ground. We report that the genetic deletion of S6K1 prevented
the enhanced phosphorylation of mTOR and downstream effec-
tors of mTORC1 in FXS model mice. Consistent with this obser-
vation, removal of S6K1 also corrected exaggerated protein
synthesis in the hippocampus of the FXSmodelmice. In addition,
we found that enhancedmGluR-LTDwasnormalized in theFmr1/
S6K1 double knockout (dKO) mice. The genetic ablation of
S6K1 also prevented several behavioral abnormalities exhibited
by FXS model mice, including increased social anxiety, impaired
novel object recognition and motor memory, and behavioral
inflexibility. Morphological studies revealed a decrease in the
number of immature spines in FXS model mice that lack S6K1.
In summary, our data suggest that genetic reduction of S6K1
can prevent molecular, synaptic, morphological, and behavioral
phenotypes associated with FXS and therefore may serve as a
potential target for therapeutic intervention in humans with FXS.326 Neuron 76, 325–337, October 18, 2012 ª2012 Elsevier Inc.RESULTS
Elevated Phosphorylation of Translational Control
Molecules and Exaggerated Protein Synthesis in Fmr1
KO Mice Are Prevented by Deletion of S6K1
To determine whether reducing S6K1 could correct phenotypes
observed in FXS model mice, Fmr1 KO mice were crossed to
mice globally lacking S6K1. S6K1 KO mice have been reported
to display deficits in early-phase long-term potentiation (LTP)
and acquisition of conditioned taste aversion (Antion et al.,
2008b). These phenotypes are distinct from those displayed by
Fmr1 KO mice and, it is important to note, it was shown that
mGluR-LTD is expressed and S6 phosphorylation is present in
S6K1 KO mice (Antion et al., 2008a). The resultant Fmr1/S6K1
KO (dKO) mice were obtained with the expected genetic
frequencies, with no observable physiological defects, and
were reproductively viable.
We first examined the phosphorylation state of key transla-
tional control molecules regulated by S6K1 in adult mice of all
four genotypes: wild-type (WT), Fmr1 KO, S6K1 KO, and dKO.
In whole hippocampal lysates, Fmr1 KOmice showed increased
levels of phosphorylated S6 at the 240/44 and 235/36 phosphor-
ylation sites when compared to WT littermates (Figures 1A and
1B). In addition, phosphorylation of eIF4B was increased in
Fmr1 KO mice (Figures 1A and 1B). In the dKO mice, the levels
of phosphorylated S6 and eIF4B were reduced to levels similar
to those in WT mice. Because S6K1 phosphorylates mTORC1
directly at serine 2448 and has been shown to regulate PI3K
and ERK signaling via feedback regulation of IRS-1, we exam-
ined mTOR and ERK phosphorylation in hippocampal lysates
from all four genotypes (Chiang and Abraham, 2005; Magnuson
Figure 2. Elevated Phosphorylation of S6 in Pyramidal Neurons of Area CA1 in Fmr1 KO Mice Is Corrected in dKO Mice
(A and B) Representative images of hippocampal sections stained for p-S6—(A) 240/44 and (B) 235/36—in pyramidal neurons of area CA1. Scale bar, 20 mm. n = 3
mice per genotype.
(C and D) Integrated intensity of phospho-S6-Alexa 568 signalmeasured across 60 neurons (10 neurons per slice, two slices permouse) for each genotype. pS6 at
(C) 240/44and (D) 235/36are represented. **p<0.01and ***p<0.001,with a two-wayANOVA (Fmr13S6K1) followedbyBonferroni post hoc tests.Errorbars,SEM.
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the Fmr1 KO mice that was reduced by the genetic ablation of
S6K1 (Figures S1A and S1B available online). Similarly, we
observed increased phosphorylation of ERK in Fmr1 KO mice
that was corrected by the ablation of S6K1 (Figures S1A and
S1B). These results support the idea that removal of S6K1 in
Fmr1 KO mice corrects not only the enhanced phosphorylation
of downstream effectors of S6K1 involved in protein synthesis,
including S6 and eIF4B, but also the feedback mechanisms
that results in aberrant signaling by correcting the elevated phos-
phorylation of both mTOR and ERK.
We also examined whether the heterozygous deletion of S6K1
could correct the molecular signaling phenotypes observed in
Fmr1KOmice. Compared toWT littermates, Fmr1KOmice lack-
ing one copy of S6K1 exhibited S6K1 phosphorylation that was
significantly increased as compared to WT littermates, which
was similar to that observed in Fmr1 KO mice (Figures S2A and
S2B). Therefore, we concluded that the deletion of one copy of
S6K1 results in hyperactive S6K1 activity, perhaps due to over-compensation, and that a complete abrogation of S6K1 would
be necessary to correct phenotypes exhibited by Fmr1 KOmice.
To examine protein synthesis, we used SUnSET (Schmidt
et al., 2009), a nonradioactive puromycin end-labeling assay.
This relatively new technique has been utilized to measure
protein synthesis during long-term associative memory consoli-
dation (Hoeffer et al., 2011). Consistent with previous studies
(Do¨len et al., 2007; Osterweil et al., 2010), basal levels of protein
synthesis were elevated in hippocampal slices from Fmr1 KO
mice (Figures 1C and 1D). In contrast, slices from dKO mice
displayed levels of puromycin labeling similar to those of WT
mice (Figures 1C and 1D).
We also assessed the phosphorylation levels of S6 at both
phosphorylation sites in hippocampal area CA1 using immuno-
histochemical methods. Stained sections from the Fmr1 KO
mice exhibited increased levels of phosphorylated S6 compared
to sections fromWTmice, with a subtle shift in the localization of
phospho-S6 to somatodendritic compartments of the pyramidal
neurons (Figures 2A and 2B). The increased S6 phosphorylationNeuron 76, 325–337, October 18, 2012 ª2012 Elsevier Inc. 327
Figure 3. Effect ofS6K1Deletion in Fmr1KO
Mice on the Protein Expression Levels of
FMRP Targets Involved in Synaptic Plas-
ticity and Protein Synthesis
(A) Representative western blots of whole hippo-
campal lysates from adult mice of all four geno-
types showing the protein expression levels of the
FMRP targets PSD-95, CaMKIIa, Shank3, eEF2,
and eIF4G identified by a recent HITS-CLIP screen
(Darnell et al., 2011).
(B) Cumulative graph with ratios expressed relative
to WT. n = 8–9 per protein per genotype. *p < 0.05,
**p < 0.01, and ***p < 0.001 with a two-way ANOVA
(Fmr1 3 S6K1) followed by Bonferroni post hoc
tests. Error bars, SEM.
See also Figure S3.
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largely localized to the cell bodies. Taken together, these find-
ings suggest that FXS mice have aberrant S6K1-dependent
protein synthesis and that genetic reduction of S6K1 in these
mice successfully restores signaling pathways important for
translational control and hence basal protein synthesis.
S6K1 Deletion Differentially Influences the Expression
Levels of Proteins Regulated by FMRP
FMRP is a key translation regulator known to play a major role in
several forms of synaptic plasticity. Previous reports indicate
that the expression of several synaptic proteins are regulated
by FMRP, including PSD-95, CaMKIIa, and MAP1B (Hou et al.,
2006; Kao et al., 2010; Lu et al., 2004; Zalfa et al., 2007), and
a recent HITS-CLIP screen by Darnell et al. (2011) reported
a large number of mRNAs that interact with FMRP, including
those that encode proteins important for synaptic plasticity.
We determined whether the expression of several of these
proteins was elevated in Fmr1 KO mice and whether abnormal
expression of the proteins could be corrected by deletion
of S6K1. We observed increased levels of synaptic proteins
PSD-95, CaMKIIa, and Shank3. In parallel, we also examined
the levels of eIF4G and eEF2, translation factors that are putative
FMRP targets (Darnell et al., 2011). Although the deletion ofS6K1
failed to normalize the elevated PSD-95 expression in Fmr1 KO
mice, the expression of CaMKIIa, and Shank3 was restored to
levels comparable to those of WT mice (Figures 3A and 3B).
We also observed increased levels of eEF2 in Fmr1 KO mice
that were normalized to WT levels in dKO mice (Figures 3A and
3B). Finally, we observed a trend of increased eIF4G levels in
Fmr1 KO mice that was significantly reduced in the S6K1 and
dKO mice. We did not observe significant differences in basal
expression of Arc/Arg 3.1 levels in whole hippocampal lysates
from the Fmr1 KO mice (Figures S3A and S3B). Because eEF2
is encoded by a 50TOP mRNA, we further explored whether the
deletion of S6K1 affected the expression of other 50TOP mRNA
protein products. We examined the levels of S6 and polyA-
binding protein (PABP), which are encoded by 50TOP mRNAs
(Meyuhas and Dreazen, 2009) but are not likely regulated by
FMRP (Darnell et al., 2011). We found no differences in levels
of S6 and PABP between the four genotypes (Figures S3A and
S3B), suggesting that the regulation of eEF2 by FMRP was not328 Neuron 76, 325–337, October 18, 2012 ª2012 Elsevier Inc.related to its mRNA containing a 50TOP. In summary, these find-
ings suggest that there is excessive translation of FMRP targets
in FXS model mice and that most, but not all, are normalized to
WT levels by decreasing the levels of S6K1.
Enhanced mGluR-LTD in Fmr1 KO Mice Is Prevented
by Deletion of S6K1
Fmr1 KO mice display enhanced hippocampal LTD in response
to stimulation of group1 metabotropic glutamate receptors with
the agonist DHPG (Huber et al., 2002). Because genetic reduc-
tion of S6K1 corrected exaggerated protein synthesis in the
Fmr1 KO mice, we asked whether this manipulation also could
correct the enhanced mGluR-LTD. We induced mGluR-LTD in
hippocampal slices from all four genotypes with an application
of 50 mM DHPG for 10 min. Consistent with previous findings,
we observed enhanced LTD in slices from Fmr1 KO mice
(Figures 4A and 4C). The enhanced mGluR-LTD was markedly
reduced in slices from the dKO mice and was similar to LTD
observed in slices from WT and S6K1 KO mice. No differences
in paired-pulse facilitation between dKO and WT slices were
found (Figure 4B). Fmr1 KO mice with a heterozygous deletion
of S6K1 still exhibited enhanced mGluR-LTD (Figures S4A
and S4B). Thus, the complete genetic ablation of S6K1 is
required to normalize the enhanced mGluR-LTD exhibited by
FXS model mice.
Abnormal Dendritic Spine Morphology in Fmr1 KO Mice
Is Corrected by Deletion of S6K1
Abnormal dendritic morphology has been reported in several
brain areas in Fmr1 KOmice and humans with FXS, as indicated
by an excessive number of spines and an increase in immature,
filopodia-like spines (He and Portera-Cailliau, 2012). Because
deleting S6K1 prevented altered translational control, exagger-
ated protein synthesis, and enhanced mGluR-LTD displayed
by Fmr1 KO mice, we measured spine density and morphology
in apical dendrites of pyramidal neurons in hippocampal area
CA1 in mice from all four genotypes. Using the rapid Golgi stain-
ing procedure, we counted spine protrusions in the apical
dendritic branches, 50 mm from the soma at intervals of 10 mm,
and spine morphology type based on previously published
guidelines (Grossman et al., 2006). We found a small but signif-
icant increase in spine density in Fmr1 KO neurons, which was
Figure 4. Exaggerated mGluR-LTD in Fmr1
KO Mice Is Reversed in dKO Slices.
(A) DHPG-induced mGluR-LTD in hippocampal
slices from WT, Fmr1, S6K1, and dKO. n = 13
slices for WT; 12 slices for Fmr1 KO, S6K1 KO, and
dKO mice. **p < 0.01 and ***p < 0.001, with
a repeated-measures ANOVA (Genotype 3 Time)
followed by Bonferroni post hoc tests.
(B) Paired-pulse facilitation in slices from dKO
mice was similar with WTmice. Percent facilitation
was calculated as a ratio of the second fEPSP to
the first fEPSP with an interpulse interval ranging
from 10 to 300 ms. n = 10 slices fromWT and from
dKO mice.
(C) Mean values of the slope of the fEPSP before
and after washout of DHPG. n = 11 slices per
genotype. ***p < 0.001, with a two-way ANOVA
(Fmr1 3 S6K1) followed by Bonferroni post hoc
tests.
Error bars, SEM. See Figure S4.
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Removing S6K1 Corrects FXS Phenotypes in Micecorrected to WT levels in the dKO neurons (Figures 5A and 5B).
Frequency histograms indicated a greater number of 10 mm
segments with high spine density in Fmr1 KO neurons compared
to the other genotypes (Figure 5D). Spine classification analysis
revealed a higher fraction of filopodia-like and thin spines
compared to stubby and mushroom spines in Fmr1 KO neurons.
In contrast, the fraction of filopodia-like spines was significantly
decreasedwith a concomitant elevation ofmature stubby/mush-
room spines in dKO neurons, comparable to levels in WT and
S6K1 KO neurons (Figure 5C). No appreciable differences were
found in spines of other types (Figure S5). These findings demon-
strate that removing S6K1 can counteract dendritic morphology
abnormalities associated with loss of FMRP.
Multiple Behavioral Phenotypes in Fmr1 KO Mice Are
Corrected by Deletion of S6K1
To assess whether the genetic reduction of S6K1 in Fmr1 KO
mice could alleviate autistic-like behaviors, we performed an
array of tests on all four genotypes. It has been reported that
the behavior of Fmr1 KO mice in these tests is sensitive to
genetic background, age, and the experimental paradigms
used (Dobkin et al., 2000; Spencer et al., 2011). Therefore, we
designed our behavioral battery to include tests that have
reported consistent differences between WT and Fmr1 KO
mice and have been conducted previously in our laboratory
(Hoeffer et al., 2008).
To examinemotor coordination and skill acquisition, we tested
performance on the rotarod using parameters similar to those
described previously (Spencer et al., 2011). Fmr1 KO mice
were significantly impaired in learning and motor coordination
across eight trials over two days as compared to their WT litter-
mates (Figure 6A). In contrast, the dKOmice displayed markedlyNeuron 76, 325–337,higher motor coordination and acquisi-
tion, performing consistently better than
the other three genotypes on both days
of the test (Figure 6A). Motor coordination
and acquisition of S6K1 KO mice wasdiminished, which differs from previous findings (Antion et al.,
2008b), perhaps due to background differences. Taken together,
the rotarod results indicate that removal of S6K1 corrects
impaired motor coordination and motor skill acquisition in FXS
model mice.
Deficits in appropriate social interaction and perspective
taking are one of the core features of autism spectrum disorders
(ASDs). Therefore, we employed the three-chambered social
interaction test to determine whether removal of S6K1 could
prevent impaired/inappropriate social behavior shown by Fmr1
KO mice. In the social approach test, experimental mice inter-
acted more with the stimulus mouse compared to the object
across all genotypes (Figure S6D). When the object was re-
placed by a novel mouse in the next phase of the test, clear
genotype-specific differences emerged (Figure 6C). Fmr1 KO
mice failed to distinguish between the familiar and novel mice,
whereas WT and dKO mice spent significantly more time inter-
acting with the novel mouse. S6K1 KO mice showed a trend
toward increased interaction with novel stimuli. These findings
indicate that removing S6K1 can correct deficits in social inter-
actions displayed by FXS model mice.
As a further test of whether removing S6K1 can prevent the
inability of Fmr1 KO mice to recognize and/or remember new
environmental stimuli and cues, we examined the behavior of
all four genotypes in the novel object recognition test (Figure 6B).
After being habituated with two objects for two consecutive days
in the arena, Fmr1 KO mice failed to recognize the novel object
introduced by replacing one of the familiar objects on the third
day of the test. In contrast, WT and dKOmice were able to distin-
guish the new object with high fidelity when tested under same
conditions. Interestingly, S6K1 KO mice were impaired in their
ability to discriminate between familiar and novel objects. TheseOctober 18, 2012 ª2012 Elsevier Inc. 329
Figure 5. Aberrant Dendritic Morphology in
Area CA1 of Fmr1 KO Mice Is Corrected in
dKO Mice
(A) Representative images of Golgi-Cox-stained
CA1 apical dendrites from all four genotypes.
Scale bar, 3 mm.
(B) Spine counts on apical dendrites per 10 mm. n =
20–22 neurons (five neurons per mouse, four mice,
and 180 10-mm segments per genotype). ***p <
0.001 by Kruskal-Wallis followed by Dunn’s
multiple comparisons post hoc tests (genotypes
compared to WT).
(C) Spine morphology studies showing the fraction
of filopodial and stubby/mushroom spines. n = 20–
22 neurons per genotype. *p < 0.05 and **p < 0.01,
with a groupwise Student’s t test. In addition,
a two-wayANOVAwasusedas shown inFigureS5.
(D) Frequency histograms representing distribu-
tion of 10 mm segments as a function of the
number of spines contained in each dendrite.
Error bars, SEM.
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Removing S6K1 Corrects FXS Phenotypes in Micefindings indicate that removal of S6K1 in Fmr1 KO mice can
restore appropriate novel object recognition memory.
We also examined whether the four genotypes showed differ-
ences in their ability to learn and recall a task and their flexibility in
modifying their responses when the task was changed using
a water-based Y-maze test. All four genotypes responded to
training and learned the test with comparable efficiency on the
first day (Figure 6D). Memory recall for the arm location of the
hidden platform also was robust on the day after training for all
four genotypes, indicating that there were no deficits in long-
term memory (Figure 6D). When the platform location was
reversed, Fmr1 KO mice displayed impairments in reversal
learning, requiring an additional 15 trials to meet criterion as
compared to WT, S6K1 KO, and dKO mice (Figures 6D and
6E). These findings suggest that upregulation of S6K1 signaling
plays a key role in behavioral inflexibility in FXS model mice.
Fmr1 KO mice also have been reported to show increased
ambulatory behavior in the open field test (Spencer et al.,
2005), which we reproduced in our behavioral cohort (Figures
S6A and S6B). In contrast, S6K1 KO littermates exhibited signif-
icantly decreased exploration and preferred the peripheral areas
versus the center of the arena. Interestingly, dKOmice displayed
open field exploration indistinguishable from the Fmr1 KO mice,
indicating that the deletion of S6K1 did not correct increased
ambulatory behavior in FXS model mice. In addition, marble-
burying behavior, a phenotype that has been used to model
obsessive-compulsive behavior in mice, was enhanced in
Fmr1 KO mice compared to WT littermates. We found that
Fmr1 KO, S6K1 KO, and dKO mice buried a higher number of
marbles compared to WT littermates (Figure S6C). These find-
ings indicate that the enhanced repetitive behavior of Fmr1 KO
mice is not rescued by the abrogation of S6K1.330 Neuron 76, 325–337, October 18, 2012 ª2012 Elsevier Inc.Excessive Weight Gain and Macro-
Orchidism in Fmr1 KO Mice Are
Corrected by Deletion of S6K1
FXS patients display neuroendocrine
dysfunction that is reflected in a general-ized increase in total body weight, macrocephaly, and enhanced
stature (Penagarikano et al., 2007). Another frequently associ-
ated feature is macro-orchidism (enlarged testicles), first
observed in male patients immediately after attaining puberty
(Hagerman et al., 1983). The weight gain phenotype in Fmr1
KO mice has been successfully rescued by reducing mGluR5
signaling (Do¨len et al., 2007). In contrast, the macro-orchidism
phenotype in FXS mice has yet to be fully corrected. Therefore,
we proceeded to determine whether removing S6K1 could
prevent weight gain andmacro-orchidism phenotypes displayed
by FXS model mice.
Male mice from six litters were monitored over 8 weeks from
the time of weaning (postnatal days 23–25) to 12 weeks of age.
We consistently observed that pups were exceedingly small
and weak if they were weaned at P20. Male littermates were
weighed once weekly at the same time. Although juvenile Fmr1
KO mice weighed slightly less than WT littermates, by 6 weeks
the rate of weight gain of the Fmr1 KO mice exceeded that of
the other three genotypes (Figures 7A and 7B) In contrast,
S6K1 KO and dKO mice were significantly smaller at 4 weeks
of age and continued to gain weight slowly. They were also
distinctly smaller in body size at 4 to 6 weeks. The dKO mice
consistently gained weight and stature to become indistinguish-
able from WT mice by 12 weeks of age and were significantly
smaller than their Fmr1 KO counterparts. Consistent with
previous reports (Pende et al., 2004), S6K1 KO mice remained
smaller in stature than all other genotypes even at 12 weeks of
age. Thus, the absence of both Fmr1 and S6K1 in the dKO
mice act in concert to restore normal body weight comparable
to that observed in WT mice.
We also examined testes harvested from adult male mice of all
four genotypes at P90-100. Testicular weights of Fmr1 KO mice
Figure 6. ASD-like Behaviors in Fmr1 KO Mice Are Corrected in dKO Mice
(A) Motor coordination and memory tested using the rotarod test. *p < 0.05 and **p < 0.01, with a repeated-measures ANOVA (Genotype 3 Trial) followed by
a Dunnett’s post hoc test (WT as control group).
(B) Preference indices of mice toward a novel object introduced in the novel object recognition test. ***p < 0.001, with a paired Student’s t test (familiar versus
novel for each genotype).
(C) Interaction time of mice with familiar and novel mice in the social novelty test. *p < 0.05 and **p < 0.01, with a paired Student’s t test (familiar versus novel for
each genotype).
(D) Behavioral flexibility in the Y-maze test. ***p < 0.001, WT versus Fmr1; ###p < 0.001, Fmr1 versus dKO with a repeated-measures ANOVA (Genotype 3 Trial)
followed by Bonferroni post hoc tests.
(E) Number of trails required by each genotype to achieve criterion in Y-maze test. **p < 0.01, with a two-way ANOVA (Fmr1 3 S6K1) followed by Bonferroni
post hoc tests.
Error bars, SEM. n = 12 WT, 12 Fmr1, 8 S6K1, and 12 dKO mice for all tests. See also Figure S6.
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Removing S6K1 Corrects FXS Phenotypes in Miceexceeded those ofWT littermates by an average of 20mg, which
was reduced with the deletion of S6K1 (Figure 7C) and overcor-
rected in the dKOmice. These findings suggest that the suppres-
sion of protein synthesis by removal ofS6K1 in the Fmr1KOmice
corrects not only the excessive body weight phenotype but
macro-orchidism as well.
DISCUSSION
Dysregulated protein synthesis is widely accepted as a core
molecular abnormality associated with FXS. Because neuronal
protein synthesis is critical for learning and memory, altered
synaptic translation is considered amajor contributor to the intel-
lectual deficits seen in FXS. In this study, we genetically manip-
ulated a translational control molecule, S6K1, in an attempt tocorrect phenotypes displayed by Fmr1 KO mice. We found
that this S6K1 deletion corrected a wide range of phenotypes
associated with FXS, including abnormal translational control,
exaggerated basal protein synthesis, abnormal protein expres-
sion of mRNA targets of FMRP, enhanced mGluR-LTD, aberrant
dendritic morphology, ASD-like behaviors, and the peripheral
features of weight gain and macro-orchidism. Since our bio-
chemical assays have focused entirely on monitoring basal rates
of signaling and translation, we believe that our findings indicate
that these effects are due to a conserved change in molecular
machinery independent of a cell-surface signal transducer.
This is particularly relevant since multiple studies have reported
dysregulation of neuronal signaling pathways apart from group 1
metabotropic glutamate receptors in FXS, including dopa-
mine receptor D1/5 signaling mediated by GRK-2, BDNF-TrkNeuron 76, 325–337, October 18, 2012 ª2012 Elsevier Inc. 331
Figure 7. Excessive Weight Gain and
Macro-Orchidism in Fmr1 KOMice Are Cor-
rected in dKO Mice
(A) Body weight data across four genotypes rep-
resented as histograms over 12 weeks. n = 14–18
at P28; n = 10–14 at P42; and n = 10 at P56, P70,
and P84. *p < 0.05, **p < 0.01, and ***p < 0.001,
with a two-way ANOVA (Fmr13 S6K1 at each time
point) followed by Bonferroni post hoc tests.
(B) Averaged body weight (mean only) of the four
genotypes as a curve over time.
(C) Mean testicular weights of male mice
(P90–100) of the four genotypes. n = 11 for WT and
Fmr1 mice; n = 8 for S6K1 mice; n = 10 for dKO
mice. **p < 0.01 and ***p < 0.001 with a two-way
ANOVA (Fmr1 3 S6K1) followed by Bonferroni
post hoc tests.
Error bars, SEM.
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Removing S6K1 Corrects FXS Phenotypes in MiceB signaling, and other Gq-mediated G protein coupled receptors
such asmuscarinic acetylcholine receptors (Castre´n et al., 2002;
Veeraragavan et al., 2011; Wang et al., 2008).
Restoration of Proper Translational Control and Protein
Synthesis in FXS Mice by Removal of S6K1
Rescuing dysregulated translation in FXS by manipulating initia-
tion and elongation factors probably is not realistic, given their
critical importance for protein synthesis-dependent growth and
proliferation in other parts of the body (Gandin et al., 2008).
Equally problematic are strategies targeting major signaling
hub kinases such as mTOR and ERK due to their other sub-
strates and their involvement in other forms of synaptic plasticity
and memory function (Costa-Mattioli et al., 2009; Richter and
Klann, 2009). An alternative approach for dampening protein
synthesis in FXS is to target signaling molecules downstream
of the hub kinases that modulate, but are not vital for, translation.
Of the handful of candidates fulfilling these criteria, S6K1
emerges because it integrates signals from both mTORC1 and
Ras-ERK pathways, both of which have been suggested to be
involved in FXS phenotypes (Wang et al., 2010). In addition,
S6K1 modulates translation at both initiation and elongation
steps via phosphorylation of multiple effectors. In addition,
S6K1 has been postulated to be an FMRP kinase (Narayanan
et al., 2008) that antagonizes FMRP function to inhibit translation
of its mRNA targets. Thus, we hypothesized that targeting S6K1
would ameliorate exaggerated protein synthesis in FXS at
multiple levels. In addition to correcting the FXS-associated
elevation in phosphorylation of translation control molecules
and exaggerated protein synthesis (Figure 1), the reduction of
S6K1 also corrected the elevated basal phosphorylation of
both mTOR and ERK (Figures S1A and S1B) in the FXS mice,332 Neuron 76, 325–337, October 18, 2012 ª2012 Elsevier Inc.which suggests that S6K1 is involved in
regulatory feedback of upstream sig-
naling pathways in FXS as well. Although
there is evidence for S6K1-mediated
phosphorylation of mTOR at serine 2448
(Chiang and Abraham, 2005), the site we
examined in Figures S1A and S1B, thereis not an obvious regulatory mechanism to explain the correction
of the elevated ERK phosphorylation in FXSmice by the removal
of S6K1 (Figures S1A and S1B). Previous studies showed that
ablation of S6K1 in mice did not result in dramatic deficits that
would exacerbate the phenotypes displayed by Fmr1 KO mice
(Antion et al., 2008a, 2008b). Although a wide range of FXS
phenotypes were corrected in the dKO mice, it would be perti-
nent to examine additional candidate molecules that modulate
protein synthesis at other translational control steps to attempt
to restore the remaining ASD-like characteristics that were not
corrected in dKO mice (Figure S6). This is especially important
in light of other studies in which targeting receptors and kinases
upstream of translation control can rectify specific subsets of
features associated with FXS (Auerbach et al., 2011; Do¨len
et al., 2007; Hayashi et al., 2007).
Our examination of the protein levels of FMRP targets in the
four genotypes has provided novel insights into altered transla-
tional control in FXSmice (Figures 3A and 3B). In a simple model,
one could assume that loss of FMRP causes increased transla-
tion of its target mRNAs and that the application of a generalized
brake on protein synthesis, such as removing S6K1, should reset
the protein levels of the FMRP targets. We found increased
protein levels of all of the FMRP target mRNAs we examined in
the Fmr1 KO mice (CaMKIIa, Shank3, eEF2, eIF4G), all of which
were reduced to WT levels in the dKO mice except for PSD-95.
We also found that basal protein expression levels of Arc/Arg 3.1
were similar in all four genotypes, which is consistent with
previous studies demonstrating that differences in Arc/Arg 3.1
in FXS mice are sensitive to changes in neuronal activity (Park
et al., 2008). Our results suggest that (1) most FMRP-regulated
mRNAs require S6K1 activity for their translation, (2) certain
mRNAs like PSD-95 may have adapted to route their translation
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of FMRP targets by S6K1 are independent of the presence of
50 TOP motif in the target mRNAs. The latter is supported by
results showing that, even though the levels of eEF2, whose
mRNA contains a 50 TOP motif, are elevated in Fmr1 KO mice,
the expression of other proteins such as S6 and PABP, whose
mRNA have 50 TOP motifs (Hornstein et al., 1999; Antion et al.,
2008a) but are not targets of FMRP (Darnell et al., 2011), showed
no changes in total protein levels (Figures S3A and S3B). These
findings are consistent with recent reports showing that 50 TOP-
mediated translation is independent of S6K1 (Magnuson et al.,
2012; Meyuhas and Dreazen, 2009). The tonic brake on general
protein synthesis exerted by S6K1 deletion likely impacts both
translation initiation and elongation, because we observed
decreased levels of eEF2 and eIF4G in S6K1 KO and dKO
mice (Figure 3). Finally, our result showing elevated Shank3
levels in Fmr1 KO mice further supports the idea of molecular
overlap of FXS and autism (Darnell et al., 2011; Herbert, 2011).
A noteworthy point is the apparent nonoverlap between
previous studies on whether basal levels of mTOR and ERK
phosphorylation are elevated in Fmr1 KO mice (Sharma et al.,
2010; Osterweil et al., 2010). As discussed thoroughly by
Osterweil and colleagues (2010), these differences stem from
methods of tissue preparation standardized for different experi-
mental objectives. Recently, however, elevated levels of phos-
phorylated mTOR and ERK were observed in nonneuronal cells
and postmortem tissue from individuals with FXS (Hoeffer
et al., 2012; Wang et al., 2012), suggesting that these molecules
are relevant markers for FXS.
Restoration of Normal mGluR-LTD and Dendritic
Morphology in FXS Mice by Removal of S6K1
Removal of S6K1 in Fmr1 KO mice prevented enhanced hippo-
campal mGluR-LTD (Figure 4A). The most parsimonious expla-
nation for this result is that reducing S6K1 levels nullifies the
increased phosphorylation of translational control molecules
such as S6 and eIF4B (Figures 1 and 2) and exaggerated
synthesis of proteins important for the expression of LTD. It
previously was shown that expression of mGluR-LTD in hippo-
campal slices from S6K1 KO mice is blocked by anisomycin
(Antion et al., 2008a), whereas the enhanced mGluR-LTD in
Fmr1 KO slices is anisomycin insensitive (Nosyreva and Huber,
2006). It remains to be determined whether mGluR-LTD is
protein synthesis dependent and whether activation of group I
mGluRs triggers protein synthesis in the dKO mice.
There have been conflicting reports of spine density changes
in the hippocampus of Fmr1 KOmice that are likely due to differ-
ences in the techniques used and the age of themice studied (He
and Portera-Cailliau, 2012). Our results showing increased spine
density and morphology phenotypes in CA1 pyramidal neurons
from Fmr1 KO mice (Figure 5) overlap with reports from other
groups that examined mice more than 3 months of age (Levenga
et al., 2011). The correction of spine density and morphology
phenotypes associated with FXS in the dKO mice suggests the
possibility of an interaction of S6K1 with the Rac1/PAK pathway
that has not been explored in neurons. Recently a role for S6K1 in
Rac1-driven platelet activation and aggregation has been
elucidated, consistent with this notion (Aslan et al., 2011). Theregulation of Shank3 in dKO mice had added implications for
spine morphology since this scaffolding protein has been shown
to influence of spine remodeling via actin-dependent mecha-
nisms (Durand et al., 2012).
Studies of the effects of S6K1 deletion have focusedmainly on
energy metabolism, caloric restriction, and insulin signaling (Sel-
man et al., 2009); there are few reports on the role of S6K1 in the
nervous system. For example, the effects of deletion of S6K1 on
neuronal morphology have not been reported. Consistent with
their small stature, we observed a significant decrease in
neuronal cell size (Figure 2) and a trend for smaller dendritic
arbors in S6K1 KO mice, although spine number and mor-
phology were not different from those of WT mice (Figure 5).
We also found the enlarged testis phenotype to be overcorrected
in the dKO mice (Figure 7C), further supporting the idea that
S6K1 is involved in the regulation of cellular size (both neuronal
and nonneuronal) and spine morphology.
Multiple ASD-like Behaviors Displayed by FXS Mice
Are Corrected by Removal of S6K1
The behavior of Fmr1 KOmice has been extensively studied and
impairments in multiple socioemotional responses, hyperac-
tivity, obsessive-repetitive behaviors, and susceptibility to
seizures have been reported, many of which are consistent
with ASD (Gross et al., 2012; Spencer et al., 2011). We found
many of these phenotypes to be reproduced in Fmr1 KO mice
in our behavioral cohort, including hyperactivity, repetitive
behaviors, and impaired social interactions. Genetic deletion of
S6K1 in Fmr1 KO mice was successful in correcting numerous
behavioral abnormalities, including social interaction, novel
object recognition, and behavioral flexibility (Figure 6). Our anal-
yses also revealed that S6K1 KO mice themselves display
impaired novel object recognition (Figure 6B) and abnormal
social behavior (Figure 6C). In contrast, S6K1 KO mice were
adept at reversal learning in the Y-maze (Figures 6D and 6E). In
addition, S6K1 KO mice were hypoactive in the open field arena
(Figures S3A and S3B) as reported earlier (Antion et al., 2008b)
but were impaired in rotarod performance (Figure 6A).
We chose to limit our biochemical, electrophysiological, and
morphological studies to the hippocampus due to the extensive
data available in this brain area for Fmr1 KO mice. However,
many of the behavioral tests we conducted have well-estab-
lished cortical-, striatal-, and amygdala-dependent compo-
nents. We observed no rescue of FXS-associated hyperactivity
and marble-burying features in dKO mice, suggesting that there
is limited impact of deleting S6K1 on altered corticostriatal
circuitry in FXS model mice. However, impairments in novel
social and object recognition were rectified, suggesting that
the S6K1 removal may results in region-specific correction of
cortical impairments in FXS mice. It will be important to examine
molecular and synaptic phenotypes in other brain regions to
obtain a more holistic idea of how the lack of S6K1 wields a
corrective influence on the FXS brain.
Peripheral Abnormalities Associated with FXS Are
Corrected by Removal of S6K1
Though FXS is largely considered a disorder of the nervous
system, FMRP expression is widespread during development,Neuron 76, 325–337, October 18, 2012 ª2012 Elsevier Inc. 333
Figure 8. Model for Regulation of Translation by FMRP and S6K1
(A) In WT mice, FMRP suppresses translation of its target mRNAs. S6K1 integrates signals from the mTORC1 and ERK1 pathways downstream of surface
receptors to promote translation via its direct and indirect regulation of initiation and elongation factors. FMRP also controls the translation and expression of key
signaling molecules as shown by the asterisk, introducing additional feedback controls. This antagonistic interplay of FMRP and S6K1 provides a dynamic
regulation of protein synthesis.
(B) In Fmr1 KOmice, the absence of FMRP results in exaggerated protein synthesis via upregulation of multiple upstream signaling molecules and downstream
effectors involved in translational control, including S6K1, promoting feed-forward, uncontrolled translation.
(C) Genetic reduction of S6K1 in the Fmr1 KOmice as modeled in the dKOmice removes the net positive drive toward exaggerated protein synthesis and applies
a tonic brake on the translation of subsets of FMRP-regulated RNA, which resets de novo protein synthesis to levels similar to that in WT mice. It is likely that the
restoration of normal translation occurs via noncanonical signaling mechanisms.
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et al., 1993). This suggests a possible role for nonneuronal
FMRP in peripheral phenotypes, the effects of which are felt
even after the actual protein expression has abated. This may
be the reason why strategies based on neuronal mediators
do not rescue peripheral symptoms such as macro-orchidism
and connective tissue abnormalities entirely (Do¨len et al.,
2007; Michalon et al., 2012). Thus, the correction of macro-
orchidism in the dKO mice was likely because S6K1 was con-
stitutively and globally reduced across tissues and organ
systems in FXS mice. It remains to be determined whether
connective tissue defects in the Fmr1 KO mice also are rescued
by deletion of S6K1.
Balanced Protein Synthesis and the Interplay of FMRP
and S6K1
We propose that the translational control of specific mRNAs in
neurons is dynamically regulated by the opposing actions of
FMRP and S6K1 (Figure 8). In WT mice, signaling downstream
of cell surface receptors activate mTORC1 and/or ERK that
results in activation of S6K1, which promotes protein synthesis
via phosphorylation ofmultiple downstreameffectors (Figure 8A).
S6K1 promotes translation, including translation of FMRP target
mRNAs, via its direct and indirect actions on initiation and
elongation factors, while at the same time limiting the translation
of FMRP target mRNAs via its action as an FMRP kinase (Nar-
ayanan et al., 2008). In FXS, the absence of FMRP creates a
perpetual translation ‘‘ON’’ state that leads to increased protein334 Neuron 76, 325–337, October 18, 2012 ª2012 Elsevier Inc.expression of FMRP targets, which not only include key media-
tors of synaptic plasticity such as PSD-95, CaMKIIa, and
Shank3, but also regulators of mTORC1 signaling such as
PIKE, TSC2, Raptor, eIF4G, and eEF2 (indicated with asterisk
in Figure 8A). Darnell et al. (2011) also identified regulators of
ERK signaling that are FMRP targets, which, if overexpressed,
also would enhance ERK signaling. Enhanced expression of
regulators of mTORC1 and ERK would form a feed-forward
loop that again would promote general translation. Removal of
S6K1 acts as a tonic brake on the exaggerated protein synthesis
in FXS by normalizing the phosphorylation and/or expression
levels of key translation control molecules such as ribosomal
protein S6, eIF4B, and eEF2 and/or by depleting the levels of crit-
ical initiation factors such as eIF4G (Figure 8C). This model is
consistent with the lowered levels of protein synthesis that occur
with deletion of S6K1 as shown by our SUnSET experiments
(Figures 1C and 1D). The experiments we conducted examining
FMRP target proteins support this model (Figures 2A and 2B);
however there were some exceptions, notably PSD-95 (Figures
2A and 2B). Future studies should help to clarify the role of
S6K1 in translational control and to identify classes of FMRP
target mRNAs that have multiple, redundant strategies to ensure
their translation. S6K1 KO mice are viable, so in the absence of
S6K1, protein synthesis still occurs via other modes of transla-
tional control (Richter and Klann, 2009) and/or the compensatory
actions by other related kinases such as S6K2 and RSK. Consis-
tent with the latter possibility, S6K1 KO mice exhibit increased
expression of S6K2 (Shima et al., 1998).
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Removing S6K1 Corrects FXS Phenotypes in MiceIn summary, our findings indicate that the removal of S6K1
corrects multiple pathophysiologies and behavioral abnormali-
ties in FXS model mice. Moreover, the genetic reduction of
S6K1 can prevent a broad range of phenotypes, including
peripheral abnormalities, associated with FXS that has not
been achieved with previous genetic manipulations. With the
recent identification of specific inhibitors of S6K1 (Pearce
et al., 2010), we visualize opportunities for translating the results
from our genetic experiments to a viable pharmacological
approach to target S6K1 to reverse a broad range of phenotypes
in FXS model mice. Such an approach may develop into a thera-
peutic option for humans with FXS in the future.
EXPERIMENTAL PROCEDURES
Mice
Fmr1 KO/S6K1 KO (dKO) mice were initially generated by crossing heterozy-
gous female mice carrying the Fmr1 mutation with heterozygous male mice
carrying the S6K1 mutation. Subsequently, all animals used for experimenta-
tion were derived from the crossing of female XFmr1+XFmr1-/ S6K+/with males
either XFmr1+Y/S6K1+/ or XFmr1-Y/S6K1+/. See the Supplemental Experi-
mental Procedures for detailed information.
Western Blots and Immunohistochemistry
Western blots were performed as described previously (Sharma et al., 2010).
For immunohistochemical analyses,micewere deeply anesthetized and trans-
cardially perfused with PBS followed by 4% PFA. Postfixed brains were
sectioned coronally at a thickness of 40 mm, followed by permeabilization,
blocking, and incubation with primary antibodies overnight. Following incuba-
tion with fluorescently tagged secondary antibodies, slices were mounted and
imaged. For details, see the Supplemental Experimental Procedures.
Electrophysiology
Transverse hippocampal slices (400 mm) were prepared from 4- to 6-week-old
mice of the four genotypes described above. Slice preparation and all LTD
experiments were performed as described previously (Sharma et al., 2010).
For details see supplementary content.
Measurement of De Novo Protein Synthesis
Transverse hippocampal slices (400 mm) were obtained from 4- to 6-week-old
mice of the four genotypes. Puromycin labeling of the slices was adapted from
procedures described previously (Hoeffer et al., 2011). For details, see the
Supplemental Experimental Procedures.
Neuroanatomy
Spine number and morphological analyses were done on rapid Golgi-Cox-
stained brain sections using a protocol described previously (Hayashi et al.,
2007). For details, see the Supplemental Experimental Procedures.
Behavioral Tests
Two independent cohorts of mice of each genotype (a total of 8–12 per
genotype) were used for the behavioral tests. Mice were 4–6 months of age,
and all mice used were male. The behavioral tests were conducted in
increasing order of difficulty and stress ranging from open field analysis,
marble-burying, rotarod, social interaction, novel object recognition, and
Y-maze choice arm reversal. All tests were performed in conditions and in
a manner as described previously (Hoeffer et al., 2008). For details, see the
Supplemental Experimental Procedures.
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